The company reported diluted net income per share of $0.12 for Q3 2024, Nareit FFO of $0.44 per share, FFO as Adjusted of $0.45 per share and AFFO of $0.41 per share. Nareit FFO and AFFO for the same period a year earlier were $0.46 and $0.40 per share, respectively.

1. 01

   The company reported diluted net income per share of $0.12 for Q3 2024, Nareit FFO of $0.44 per share, FFO as Adjusted of $0.45 per share and AFFO of $0.41 per share. Nareit FFO and AFFO for the same period a year earlier were $0.46 and $0.40 per share, respectively.

2. 02

   The company changed its full-year 2024 diluted earnings per share outlook from $0.27 to $0.31 to $0.40 to $0.42, and its diluted FFO as Adjusted per share outlook from $1.77 to $1.81 to $1.79 to $1.81. It also changed its Total Merger-Combined Same-Store Cash (Adjusted) NOI growth outlook from 2.75% to 4.25% to 3.5% to 4.5%.

3. 03

   The company said it signed 465,000 square feet of lab leases in Q3 2024, with a positive 10% cash rent mark-to-market on renewals. Year to date through October 24, it had executed 1.7 million square feet of lab leases, and signed letters of intent for an additional 575,000 square feet.

4. 04

   Healthpeak said Total Merger-Combined Same-Store Cash (Adjusted) NOI growth was 4.1% for Q3, and that it increased its expected merger-related synergies for 2024 to approximately $50 million. The company cited property management internalization as the driver.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.